Cataract surgery and nonsteroidal antiinflammatory drugs | ASCRS
Committee Report
Cataract surgery and nonsteroidal antiinflammatory drugs
September 2016
Authors: Richard S. Hoffman, MD, Rosa Braga-Mele, MD, Kendall Donaldson, MD, Geoffrey Emerick, MD, Bonnie Henderson, MD, Malik Kahook, MD, Nick Mamalis, MD, Kevin M. Miller, MD, Tony Realini, MD, MPH, Neal H. Shorstein, MD, Richard K. Stiverson, MD, Barbara Wirostko, MD
You must be logged in to view this content

This resource is only available for ASCRS Members. Please log in using the teal "Login" button in the top right-hand corner to log in.

Report Summary

Nonsteroidal antiinflammatory drugs (NSAIDs) have become an important adjunctive tool for surgeons performing routine and complicated cataract surgery. These medications have been found to reduce pain, prevent intraoperative miosis, modulate postoperative inflammation, and reduce the incidence of cystoid macular edema (CME). Whether used alone, synergistically with steroids, or for specific high-risk eyes prone to the development of CME, the effectiveness of these medications is compelling. This review describes the potential preoperative, intraoperative, and postoperative uses of NSAIDs, including the potency, indications and treatment paradigms and adverse effects and contraindications. A thorough understanding of these issues will help surgeons maximize the therapeutic benefits of these agents and improve surgical outcomes.

We use cookies to measure site performance and improve your experience. By continuing to use this site, you agree to our Privacy Policy and Legal Notice.